These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23986347)

  • 1. In reply.
    Valachis A; Polyzos NP
    Oncologist; 2013; 18(8):e26-7. PubMed ID: 23986347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy with zoledronic Acid and menopausal status.
    Zheng YY; Zhu JH
    Oncologist; 2013; 18(8):e24. PubMed ID: 23986345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid and its accentuating effect on tumor radiosensitivity.
    Kapoor S
    Oncologist; 2013; 18(8):e21. PubMed ID: 23986343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of zoledronate in aromatase activity should be considered in future studies.
    Ghobadifar MA
    Oncologist; 2013; 18(8):e25. PubMed ID: 23986346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γδ T cells predict outcome in zoledronate-treated breast cancer patients.
    Welton JL; Martí S; Mahdi MH; Boobier C; Barrett-Lee PJ; Eberl M
    Oncologist; 2013; 18(8):e22-3. PubMed ID: 23986344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):852-4. PubMed ID: 16491627
    [No Abstract]   [Full Text] [Related]  

  • 7. Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
    Diel I; Aebi S
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S11-5. PubMed ID: 20427027
    [No Abstract]   [Full Text] [Related]  

  • 8. Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer.
    Bertoldo F; Tonini G; Vincenzi B; Santini D
    Nat Rev Clin Oncol; 2009 Apr; 6(4):191-2. PubMed ID: 19333223
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
    Tonyali O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2010 Nov; 11(16):2715-25. PubMed ID: 20977404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
    Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
    Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ..
    Gnant M; Eidtmann H
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S2-6. PubMed ID: 20427029
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
    Yaman E; Benekli M; Coskun U; Ozturk B; Kaya AO; Yildiz R; Buyukberber S
    Ann Oncol; 2008 Feb; 19(2):397-8; author reply 398. PubMed ID: 18260185
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
    Valachis A; Polyzos NP; Coleman RE; Gnant M; Eidtmann H; Brufsky AM; Aft R; Tevaarwerk AJ; Swenson K; Lind P; Mauri D
    Oncologist; 2013; 18(4):353-61. PubMed ID: 23404816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A
    J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
    [No Abstract]   [Full Text] [Related]  

  • 17. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
    Shapiro CL; Halabi S; Hars V; Archer L; Weckstein D; Kirshner J; Sikov W; Winer E; Burstein HJ; Hudis C; Isaacs C; Schilsky R; Paskett E
    Eur J Cancer; 2011 Mar; 47(5):683-9. PubMed ID: 21324674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CALGB 78909: Phase III trial of intravenous zoledronic acid in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.
    Clin Adv Hematol Oncol; 2005 Feb; 3(2):105-6. PubMed ID: 16166977
    [No Abstract]   [Full Text] [Related]  

  • 19. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
    Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
    Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which bisphosphonate to treat bone metastases?
    Costa L
    Lancet Oncol; 2014 Jan; 15(1):15-6. PubMed ID: 24332513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.